论文部分内容阅读
在设计良好的随机临床试验中,洛匹那韦/利托那韦(LPV/r)与其他抗反转录病毒治疗(ART)联合应用,使经治艾滋病病人获得持久的病毒学疗效,并且重建了宿主免疫功能,同时LPV/r对经治病人亦具有较高的耐药屏障。LPV/r·作为一个成熟的基准药物,常用于与其他蛋白酶抑制剂的非劣效性比较研究。但是考虑到LPV/r相关胃肠道不良反应和高甘油三酯血症及高胆固醇血症,当出现高脂血症时需要同时给予降脂药以降低冠心病的风险。此综述对成人Ⅰ型艾滋病病毒(HIV-1)感染经治病人,应用包含LPV/r抗病毒治疗方案的临床疗效、安全性及耐药研究进展进行较全面系统的总结。
In a well-designed, randomized clinical trial, lopinavir / ritonavir (LPV / r) is administered in combination with other antiretroviral therapy (ART) to achieve a long-term virologic response to treated AIDS patients and Reconstituted host immune function, while LPV / r on the treated patients also have a high resistance barrier. As a mature benchmark drug, LPV / r is often used in comparative studies with other protease inhibitors for noninferiority. However, taking into account the LPV / r-related gastrointestinal adverse reactions and hypertriglyceridemia and hypercholesterolemia, when the emergence of hyperlipidemia need to be given at the same time lipid-lowering drugs to reduce the risk of coronary heart disease. This review summarizes the clinical efficacy, safety and drug resistance of patients with HIV-1 infection including LPV / r antiviral therapy.